B7-H3 targeted CAR-NK (Cytocraft Biopharmaceutical)

B7-H3 CAR-NK(赛德特生物)

Report date: 2026/05/18 20:02:07

Base Information

Drug NameB7-H3 targeted CAR-NK (Cytocraft Biopharmaceutical)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionAnti-CD276
TargetsCD276 antigen
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesCytocraft Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCytocraft Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A